663 related articles for article (PubMed ID: 12430360)
1. The Human Genome Project: a public good.
Hudson K
Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
[No Abstract] [Full Text] [Related]
2. The role of the private sector in biotechnology: research and development.
Feisee L
Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359
[No Abstract] [Full Text] [Related]
3. Science and the law. Working through the patent problem.
Walsh JP; Cohen WM; Arora A
Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
[No Abstract] [Full Text] [Related]
4. Human genomes, public and private.
Nature; 2001 Feb; 409(6822):745. PubMed ID: 11236960
[No Abstract] [Full Text] [Related]
5. In pursuit of patents: 21st century challenges.
Blatt RJ
J Biolaw Bus; 1998; 1(4):4-7. PubMed ID: 11657745
[No Abstract] [Full Text] [Related]
6. Wrong map: why public science can't really be public.
Mukherjee S
New Repub; 2000 May; 222(19):14-5. PubMed ID: 12465651
[No Abstract] [Full Text] [Related]
7. The times they are a-changin'.
Patrinos A; Drell D
Nature; 2002 Jun; 417(6889):589-90. PubMed ID: 12050635
[No Abstract] [Full Text] [Related]
8. Genomic capital: public cultures and market logics of corporate biotechnology.
Rajan KS
Sci Cult (Lond); 2003 Mar; 12(1):87-121. PubMed ID: 15971369
[No Abstract] [Full Text] [Related]
9. Sustainability and the balancing of the health care and innovation agendas: the commercialization of genetic research.
Caulfield T
Sask Law Rev; 2003; 66(2):629-45. PubMed ID: 15212021
[No Abstract] [Full Text] [Related]
10. Industry and academia in transition.
Kennedy D
Science; 2003 Nov; 302(5649):1293. PubMed ID: 14631000
[No Abstract] [Full Text] [Related]
11. Public sector seeks to bridge 'valley of death'.
Moran N
Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
[No Abstract] [Full Text] [Related]
12. Patent medicine.
Baker D
J Public Health Policy; 2001; 22(3):275-9. PubMed ID: 11603309
[No Abstract] [Full Text] [Related]
13. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
Westerlund L
Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
[No Abstract] [Full Text] [Related]
14. Celera turns to public genome data to speed up endgame.
Smaglik P; Butler D
Nature; 2000 Jan; 403(6766):119. PubMed ID: 10646565
[No Abstract] [Full Text] [Related]
15. Venter backs call for more public funds.
Wadman M
Nature; 1998 May; 393(6683):296. PubMed ID: 9620787
[No Abstract] [Full Text] [Related]
16. Regulating scientific research: intellectual property rights and the norms of science.
Rai AK
Northwest Univ Law Rev; 1999; 94(1):77-152. PubMed ID: 12784815
[No Abstract] [Full Text] [Related]
17. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
18. A modest proposal: toward improved access to biotechnology research tools by implementing a broad experimental use exception.
Hoffman DC
Cornell Law Rev; 2004 May; 89(4):993-1043. PubMed ID: 15174465
[No Abstract] [Full Text] [Related]
19. The changing norms of the life sciences.
Shorett P; Rabinow P; Billings PR
Nat Biotechnol; 2003 Feb; 21(2):123-5. PubMed ID: 12560827
[No Abstract] [Full Text] [Related]
20. Biotechnology transfer at the National Institutes of Health.
Chen PS
Qual Assur; 1993 Dec; 2(4):345-52. PubMed ID: 7952969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
